Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals

Definitions

• the present invention relates to the new use of thiazoloisoindolinone derivatives for the production of
• the present invention relates to the use of compounds of the general formula I.
• R is a hydrogen atom or a straight-chain or 'branched, saturated or unsaturated aliphatic radical having 1-7 carbon atoms, which may optionally be substituted by phenyl, or a phenyl ring, which
• C 1 -C 4 alkyl optionally substituted one or more times by C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxy, trifluoromethyl, C 1 -C 4 alkylsulfonyl or halogen, such as fluorine, chlorine or bromine, n stands for the numbers 0, 1 or 2, and their pharmacologically acceptable salts and tautomers.
• Patent applications are also described in J. Org. Chem. 30, 1506 (1965) and J. Org. Chem. 34, 165 (1969).
• AZT 3'-azido-3'-deoxy-thymidine
• Zidovudine or Retrovir R 3'-azido-3'-deoxy-thymidine
• Retrovir R 3'-azido-3'-deoxy-thymidine
• the compounds of the general formula I do not have these disadvantages. They have an antiviral effect without being cytotoxic in pharmacologically relevant doses.
• the compounds of the present invention have valuable pharmacological properties. They are particularly suitable for the therapy and prophylaxis of infections caused by DNA viruses such as the herpes simplex virus, the cytomegalovirus, papilloma viruses, the varicella zoster virus or
• Epstein-Barr virus or RNA viruses such as toga viruses or in particular retroviruses such as the oncoviruses HTLV-I and II, and the lentiviruses Visna and human immunodeficiency virus HIV-1 and -2, are caused.
• the compounds of the formula I appear to be particularly suitable for the treatment of the clinical manifestations of retroviral HIV infection in humans, such as persistent generalized lymphadenopathy (PGL), the advanced stage of the AIDS-related complex (ARC) and the clinical picture of AIDS.
• PDL persistent generalized lymphadenopathy
• ARC advanced stage of the AIDS-related complex
• the compounds mentioned could advantageously be used prophylactically or therapeutically in the treatment of diseases in which one retroviral infection is of pathophysiological, symptomatic or clinical relevance.
• R denotes a straight-chain or branched, saturated or unsaturated aliphatic radical, in particular an alkyl radical, having 1-7, preferably 1-4 carbon atoms, such as, for example, B. methyl, ethyl or isopropyl.
• the ali phatic radical can also be substituted by a phenyl group, so that R is a phenylalkyl radical, such as. B. benzyl.
• the unsaturated radicals are C 2 -C 7 alkenyl or C 2 - C 7 alkynyl groups in question.
• R can also represent a phenyl ring which is unsubstituted or one or more times
• the phenyl ring is preferably mono- or disubstituted.
• suitable substituents are the methyl, ethyl, methoxy or ethoxy group.
• R represents a phenyl group which may be mono- to trisubstituted by the following radicals: C 1 -C 4 alkyl, especially methyl, ethyl, n-propyl or i-propyl; Halogen, especially fluorine, chlorine or bromine; Trifluoromethyl, hydroxy, -C ⁇ C4 alkoxy, especially methoxy or ethoxy.
• Derivatives which have a substituent in the 3- or 4-position of the phenyl ring are particularly preferred. Disubstituted
• Phenyl radicals are preferably the derivatives substituted in the 3,5-, 3,4-, 2,4- or 2,5-position.
• the medicaments containing at least one compound of the formula I for the treatment of viral infections can be administered enterally or parenterally in liquid or solid form.
• the usual forms of application come into play here
• Water is preferably used as the injection medium, which contains the additives customary for injection solutions, such as stabilizers, solubilizers and buffers.
• additives are e.g. Tartrate and citrate buffers, ethanol, complexing agents such as ethylene diamine tetraacetic acid and its non-toxic salts, high molecular weight
• Liquid carriers for injection solutions must be sterile and are preferably filled into ampoules.
• Solid carriers are, for example, starch, lactose, mannitol, methyl cellulose, talc, highly disperse silicic acids, higher molecular fatty acids, such as stearic acid, gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high-molecular polymers, such as polyethylene glycols, etc.
• Preparations suitable for oral applications can, if desired, contain flavorings or sweeteners.
• the dosage can depend on various factors, such as the mode of administration, species, age or individual condition.
• the compounds according to the invention are usually applied in amounts of 0.1-100 mg, preferably 0.2-80 mg per day and per kg of body weight. It is preferred to distribute the daily dose over 2-5 applications, with each
• Application 1-2 tablets with an active ingredient content of 0.5 - 500 mg can be administered.
• the tablets can also be delayed, which reduces the number of applications per day to 1-3.
• the active substance content of the retarded tablets can be 2 - 1000 mg.
• the active ingredient can also be given by continuous infusion, with the amounts of 5-1000 mg per day usually being sufficient.
• the screening test system contains the purified RT from HIV-1, which was expressed by genetic engineering methods in E. coli, as well as the components of the initiation complex, such as the in vitro transcripts of the HIV-LTR with the neighboring primer binding site as a template and one for Primer binding site complementary 18mer oligonucleotide as a primer.
• the [ 3 H] -thymidine-5'-triphosphate incorporation was measured by counting in the ß-counter.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6418011

Family Applications (1)

Country Status (16)

Cited By (1)

Families Citing this family (7)

Citations (1)

• 1990
  • 1990-11-10 DE DE4035809A patent/DE4035809A1/de not_active Withdrawn
• 1991
  • 1991-10-23 TW TW080108378A patent/TW198680B/zh active
  • 1991-11-06 DE DE59104441T patent/DE59104441D1/de not_active Expired - Fee Related
  • 1991-11-06 US US08/050,067 patent/US5397794A/en not_active Expired - Fee Related
  • 1991-11-06 CA CA002095249A patent/CA2095249A1/en not_active Abandoned
  • 1991-11-06 MX MX9101948A patent/MX9101948A/es unknown
  • 1991-11-06 WO PCT/EP1991/002101 patent/WO1992008457A1/de not_active Ceased
  • 1991-11-06 AT AT91919525T patent/ATE117552T1/de not_active IP Right Cessation
  • 1991-11-06 AU AU88650/91A patent/AU8865091A/en not_active Abandoned
  • 1991-11-06 ES ES91919525T patent/ES2069313T3/es not_active Expired - Lifetime
  • 1991-11-06 EP EP91919525A patent/EP0556245B1/de not_active Expired - Lifetime
  • 1991-11-06 JP JP3517357A patent/JPH06501690A/ja active Pending
  • 1991-11-07 IL IL99989A patent/IL99989A0/xx unknown
  • 1991-11-08 PT PT99463A patent/PT99463A/pt not_active Application Discontinuation
  • 1991-11-08 IE IE389891A patent/IE913898A1/en unknown
  • 1991-11-08 ZA ZA918862A patent/ZA918862B/xx unknown
  • 1991-11-09 CN CN91110726A patent/CN1061341A/zh active Pending

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events